Immunotherapeutic approaches in chronic myelogenous leukemia.
Chronic myeloid leukemia (CML) is a stem cell disease in which BCR/ABL plays an important role as oncoprotein and also as a molecular and immunogenic target. In fact, several molecular targeted drugs and immunotherapies have been developed for this disease. In the current article, several immunotherapeutic approaches in CML, including interferon-alpha and vaccination, are discussed along with results from clinical trials and the value of such immunotherapies in the imatinib-era.
Guilhot
François
F
Department of Oncology-Haematology and Cell Therapy, EA 3805 and Clinical Research Centre, CHU de Poitiers, Poitiers, France. f.guilhot@chu-poitiers.fr
Roy
Lydia
L
Saulnier
Pierre-Jean
PJ
Guilhot
Joëlle
J
Barra
Anne
A
Gombert
Jean-Marc
JM
Turhan
Ali
A
D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D007167:Immunotherapy / Q000379:methods*; D016898:Interferon-alpha; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D010879:Piperazines; D011743:Pyrimidines; D014612:Vaccines
D001549:Benzamides; D016898:Interferon-alpha; D010879:Piperazines; D011743:Pyrimidines; D014612:Vaccines; D000068877:Imatinib Mesylate